- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.09. | Henkel befördert Frank Tenbrock zum CDIO | 27 | CIO | ||
| 14.08. | Cardio Diagnostics Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 22.07. | Cardio Diagnostics: Medicare gibt vorläufige Erstattungssätze für Herztests bekannt | 1 | Investing.com Deutsch | ||
| 22.07. | Medicare sets preliminary payment rates for Cardio Diagnostics tests | 1 | Investing.com | ||
| 08.07. | Studienkooperation mit AGEPHA Pharma treibt Aktie von Cardio Diagnostics an | - | Investing.com Deutsch | ||
| 18.06. | Medicover AB: Lukasz Krause new Chief Digital Information Officer (CDIO) Medicover | 263 | GlobeNewswire (Europe) | Lukasz Krause will assume the role of CDIO as of 1 July 2025 and be part of the executive management team of Medicover.
Lukasz brings a wealth of experience in IT management having successfully overseen... ► Artikel lesen | |
| CARDIO DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 10.06. | Cardio Diagnostics secures Japan patent for heart disease biomarkers | 1 | Investing.com | ||
| 10.06. | Cardio Diagnostics sichert sich japanisches Patent für Herzerkrankungsbiomarker | - | Investing.com Deutsch | ||
| 09.06. | Cardio Diagnostics Holdings, Inc. (CDIO): A Bull Case Theory | 1 | Insider Monkey | ||
| 29.05. | Cardio Diagnostics Regains Nasdaq Compliance After Reverse Stock Split | 1 | RTTNews | ||
| 29.05. | Cardio Diagnostics regains Nasdaq compliance following reverse stock split | 2 | Seeking Alpha | ||
| 28.05. | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Cardio Diagnostics Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.05. | Cardio Diagnostics announces 1-for-30 reverse stock split | 2 | Seeking Alpha | ||
| 08.05. | Cardio Diagnostics enacts 1-for-30 reverse stock split | 1 | Investing.com | ||
| 08.05. | Cardio Diagnostics drops on 1-for-30 reverse stock split | 1 | Seeking Alpha | ||
| 08.05. | Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split | 990 | Business Wire | CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. ("Cardio" or the "Company") (NASDAQ: CDIO), today announced a 1-for-30 reverse stock split of its common stock effective with the market opening... ► Artikel lesen | |
| 08.04. | Cardio Diagnostics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - S-1/A, General form for registration of securities | ||
| BIOXXMED | 0,120 | 0,00 % | PTA-News: bioXXmed AG: Ergebnis der Zeichnung der Wandelschuldverschreibung | DJ PTA-News: bioXXmed AG: Ergebnis der Zeichnung der Wandelschuldverschreibung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Ergebnis der Zeichnung der Wandelschuldverschreibung... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 1,495 | -0,20 % | Ocugen plant drei Zulassungsanträge für Gentherapien gegen Erblindung bis 2028 | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,885 | -4,84 % | EQS-News: Bio-Gate AG: Bio-Gate veröffentlicht Halbjahreszahlen und bestätigt den Ausblick für 2025 | EQS-News: Bio-Gate AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
Bio-Gate veröffentlicht Halbjahreszahlen und bestätigt den Ausblick für 2025
30.09.2025 / 15:07... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,467 | +0,65 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations | Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| VAXART | 0,280 | +3,63 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,410 | +4,44 % | Burcon NutraScience Corporation: Burcon Announces New Board Members and Results of Shareholder Meeting | Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,820 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors | Patent supports AIM's strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical... ► Artikel lesen | |
| IMMUNIC | 0,836 | +1,46 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in October | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in October
01.10.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CEL-SCI | 8,400 | +4.192 % | XFRA LSR: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
CARDIO DIAGNOSTICS HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARDIO DIAGNOSTICS HOLDINGS INC finden Sie auf Wallstreet Online.